News & Events:ABBV

Why SpringWorks Shares Are Soaring Today Premarket

Here's a roundup of top developments in the biotech space over the last 24 hours: The FDA has requested additional information on the Chemistry Manufacturing and Controls of the newly manufactured INmune Bio Inc's  XPro1595. As part of the communication, the FDA placed the company's Investigational New Drug application for the Phase 2 trial of XPro in Alzheimer's Disease on clinical hold.

- SELECT-AXIS 2 highlights the efficacy and safety data of upadacitinib in patients with non-radiographic axial spondyloarthritis, and in patients with radiographic axial spondyloarthritis with an inadequate response to biologic disease-modifying antirheumatic drugs- SELECT-PsA 1 & 2 highlight the efficacy and safety data of RINVOQ at two years in psoriatic arthritis patients with an inadequate...

AbbVie has outperformed the market over the past 5 years by 7.1% on an annualized basis producing an average annual return of 17.45%. Currently, AbbVie has a market capitalization of $260.97 billion. Buying $1000 In ABBV: If an investor had bought $1000 of ABBV stock 5 years ago, it would be worth $2,226.33 today based on a price of $147.68 for ABBV at the time of writing.

  See all analyst ratings upgrades.   See all analyst ratings downgrades.   See all analyst ratings initiations.

Within the last quarter, AbbVie has observed the following analyst ratings: According to 8 analyst offering 12-month price targets in the last 3 months, AbbVie has an average price target of $169.38 with a high of $200.00 and a low of $140.00. Below is a summary of how these 8 analysts rated AbbVie over the past 3 months. This average price target has increased by 11.75% over the past month.

Abbvie Inc (ABBV): * ABBVIE PRESENTS POSITIVE DATA FROM PHASE 3 STUDY OF CARIPRAZINE FOR THE ADJUNCTIVE TREATMENT OF MAJOR DEPRESSIVE DISORDER AT 2022 APA ANNUAL MEETING Source text for Eikon: Further company coverage:

NORTH CHICAGO, Ill. AbbVie's (ABBV) supplemental New Drug Application for cariprazine was supported by two positive registration-enabling studies, of which one was Study 3111-301-001.

EMA's CHMP Recommends AbbVie's Upadacitinib For Ulcerative Colitis

Abbvie Inc (ABBV): * CHMP RECOMMENDS EUROPEAN COMMISSION APPROVAL OF UPADACITINIB FOR THE TREATMENT OF ADULTS WITH MODERATE TO SEVERE ULCERATIVE COLITIS. * CHMP POSITIVE OPINION IS BASED ON RESULTS FROM THREE PHASE 3 STUDIES: TWO FOR INDUCTION AND ONE FOR MAINTENANCE. * IF APPROVED BY EUROPEAN COMMISSION, THIS WOULD BE UPADACITINIB'S FIFTH THERAPEUTIC INDICATION IN EU.

NORTH CHICAGO, Ill.

On CNBC's "Halftime Report Final Trades," Kevin O'Leary, known as "Mr. Wonderful," said that consumer goods, especially baby powder and baby formula, have been "in the news lately." O'Leary added, "Nestle is a great trade name" and a global behemoth, with 50% of its sales in the US.

Biotech stocks advanced in the week ending May 22, defying the broader market retreat. The spread of the monkey pox virus in the U.S. and Europe sparked a rally in companies working on vaccine candidates against viruses. NanoViricides, Inc. also advanced strongly following positive clinical updates provided by the company.

The law firm of Kessler Topaz Meltzer & Check, LLP informs investors that the firm has filed a securities class action lawsuit in the United States District Court for the Northern District of Illinois against AbbVie, Inc. (ABBV) on behalf of all persons and entities who purchased or otherwise acquired AbbVie (ABBV) securities between April 30, 2021, and August 31, 2021, inclusive.

AbbVie Submits FDA Application For Continuous, 24-Hour Infusion Therapy For Parkinson's

CNBC's "Fast Money: Halftime Report" delivers market-moving news to investors. The commentary delivered by hosts of the show often moves the stocks mentioned. Kevin O'Leary of "Shark Tank" bought shares in the following companies: Cognex Corporation Shannon Saccocia of SVB Private said she sold her position in Cognex, citing underperformance in the stock.

Abbvie Inc (ABBV): * ABBVIE SUBMITS NEW DRUG APPLICATION TO U.S. FDA FOR INVESTIGATIONAL ABBV-951 FOR THE TREATMENT OF ADVANCED PARKINSON'S DISEASE. * Abbvie Inc (ABBV) - WILL CONTINUE TO PURSUE REGULATORY SUBMISSIONS FOR ABBV-951 ACROSS INTERNATIONAL MARKETS THROUGHOUT YEAR Source text for Eikon: Further company coverage:

NORTH CHICAGO, Ill. The submission is based on results from a Phase 3, head-to-head, randomized and controlled clinical trial demonstrating statistically significant improvement in "On" time without troublesome dyskinesia compared to oral immediate-release carbidopa/levodopa. ABBV-951 is designed to provide a first-of-its-kind, 24-hour, continuous subcutaneous delivery of CD/LD.

Someone with a lot of money to spend has taken a bullish stance on AbbVie. And retail traders should know. We noticed this today when the big position showed up on publicly available options history that we track here at Benzinga. Whether this is an institution or just a wealthy individual, we don't know. So how do we know what this whale just did?

NEW YORK, May 19, 2022 Levi & Korsinsky, LLP notifies investors in AbbVie Inc. (ABBV) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of AbbVie (ABBV) investors who were adversely affected by alleged securities fraud between April 30, 2021 and August 31, 2021.